{
    "nct_id": "NCT06544655",
    "official_title": "A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies",
    "inclusion_criteria": "* Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).\n* Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).\n* Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of or with active interstitial lung disease or pulmonary fibrosis.\n* Active, known, or suspected autoimmune disease.\n* Serious uncontrolled medical disorders.\n* New onset, non-catheter-associated venous thromboembolism within the past 6 months.\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
    "miscellaneous_criteria": ""
}